AbbVie Inc (NYSE:ABBV) has coverage initiated with a Outperform rating and $105.00 price target

ME Staff
-
0

Analyst Ratings For AbbVie Inc (NYSE:ABBV)

Today, Berenberg Bank initiated coverage on AbbVie Inc (NYSE:ABBV) with a Hold with a price target of $105.00.

There are 4 sell ratings, 8 hold ratings, 5 buy ratings, 0 strong buy ratings on the stock.

The current consensus rating on AbbVie Inc (NYSE:ABBV) is Hold with a consensus target price of $104.6376 per share, a potential 9.86% upside.

Some recent analyst ratings include

  • 7/12/2018-Berenberg Bank initiated coverage with a Hold rating.
  • 6/1/2018-Piper Jaffray Companies was Downgraded by analysts at Piper Jaffray Companies from a “Overweight ” rating to a ” Neutral” rating. They now have a $66.62 price target on the stock, up previously from $125.86 .
  • 5/30/2018-Deutsche Bank was Downgraded by analysts at Deutsche Bank from a “Neutral ” rating to a ” Underperform” rating. They now have a $65.61 price target on the stock, up previously from $125.86 .
  • 5/24/2018-Goldman Sachs Group was Downgraded by analysts at Goldman Sachs Group from a “Conviction-Buy ” rating to a ” Buy” rating. They now have a N/A price target on the stock.

Recent Insider Trading Activity For AbbVie Inc (NYSE:ABBV)
AbbVie Inc (NYSE:ABBV) has insider ownership of 0.07% and institutional ownership of 69.42%.

  • On 6/27/2018 Glenn F Tilton, Director, bought 5,400 with an average share price of $91.90 per share and the total transaction amounting to $496,260.00.
  • On 6/20/2018 Edward J. Rapp, Director, bought 1,013 with an average share price of $98.63 per share and the total transaction amounting to $99,912.19.
  • On 6/15/2018 Timothy J Richmond, SVP, sold 17,588 with an average share price of $99.47 per share and the total transaction amounting to $1,749,478.36.
  • On 3/1/2018 Carlos Alban, EVP, sold 83,574 with an average share price of $114.49 per share and the total transaction amounting to $9,568,387.26.
  • On 3/1/2018 Laura J Schumacher, Insider, sold 25,000 with an average share price of $117.85 per share and the total transaction amounting to $2,946,250.00.
  • On 3/1/2018 William J Chase, CFO, sold 70,928 with an average share price of $117.18 per share and the total transaction amounting to $8,311,343.04.
  • On 2/28/2018 Richard A Gonzalez, Chairman, sold 8,280 with an average share price of $117.88 per share and the total transaction amounting to $976,046.40.

About AbbVie Inc (NYSE:ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection for autoimmune diseases; IMBRUVICA, an oral therapy for patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. It serves wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has a collaboration with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; International Myeloma Foundation; Calibr and Scripps Research; The Institute for Research in Immunology and Cancer ? Commercialization of Research; and the Université de Montréal. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Recent Trading Activity for AbbVie Inc (NYSE:ABBV)
Shares of AbbVie Inc closed the previous trading session at 95.14 up +0.18 0.19% with 1629547 shares trading hands.